Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

Diener, Hans‐Christoph; L. Sacco, Ralph; Donald Easton, J.; B. Granger, Christopher; A. Bernstein, Richard; Uchiyama, Shinichiro; Kreuzer, Jörg; Cronin, Lisa; Cotton, Daniel; Grauer, Claudia; Brueckmann, Martina; A. Chernyatina, M.; A. Donnan, Geoffrey; M. Ferro, José; Grond, Martin; Kallmünzer, Bernd; Krupiński, Jerzy; Lee, Byung‐Chul; Lemmens, Robin; Masjuán, Jaime; Odinak, Miroslav; L. Saver, Jeffrey; D. Schellinger, Peter; Toni, Danilo; Toyoda, Ḱazunori

doi:10.1056/nejmoa1813959

Public

Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

Published in New England Journal of Medicine • May 15, 2019

Authors:

Hans‐Christoph Diener

Ralph L. Sacco

J. Donald Easton

Abstract

BACKGROUND: Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source. An earlier randomized trial showed that rivaroxaban is no more effective than aspirin in preventing recurrent stroke after a presumed emboli...

Subject

Embolic stroke

Dabigatran

Stroke (engine)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!